Table 2B.

Conclusions of DED Studies by R. Dana's Team at Harvard University Schepens Eye Research Institute (2009-13)

Year	Title	Conclusion
2013	Chronic Dry Eye Disease is Principally Mediated by Effector Memory Th17 Cells 4	Effector memory Th17 cells are primarily responsible for maintaining the chronic and relapsing course of DED
2012	Dry Eye Disease: An Immune-Mediated Ocular Surface Disorder 78	Fundamental links between inflammation and dry eye disease.
2012	Efficacy of Topical Blockade of Interleukin-1 in Experimental Dry Eye Disease 79	Topical treatment with IL-1Ra is effective in ameliorating the clinical signs of the dry eye disease as well as in reducing underlying inflammation.
2012	Expression of Toll-Like Receptor 4 Contributes to Corneal Inflammation in Experimental Dry Eye Disease 80	DED increases the corneal expression of TLR4 and that TLR4 participates in the inflammatory response to ocular surface desiccating stress.
2012	Ocular Surface Immunity: Homeostatic Mechanisms and Their Disruption in Dry Eye Disease 81	Disruption of afferent and efferent immune regulatory mechanisms are responsible for the chronicity of the disease, its symptoms, and its clinical signs.
2011	Interferon-Gamma-Secreting NK Cells Promote Induction of Dry Eye Disease 82	IFN-γ-secreting NK cells can promote induction of DED via direct target tissue damage and indirect influence on the priming phase of an adaptive immune response in secondary lymphoid tissue.
2011	Therapeutic Efficacy of Topical Epigallocatechin Gallate in Murine Dry Eye 83	Topical EGCG treatment is able to reduce the clinical signs and inflammatory changes in DED by suppressing the inflammatory cytokine expression and infiltration of CD11b+ cells in the cornea.
2010	Evidence of Corneal Lymphangiogenesis in Dry Eye Disease A Potential Link to Adaptive Immunity? 84	Low-grade inflammation associated with DED is an inducer of lymphangiogenesis without accompanying hemangiogenesis.
2009	Autoimmunity in Dry Eye Is Due to Resistance of Th17 to Treg Suppression 85	Pathogenic T cell subset (Th17) in DED is associated specifically with Treg dysfunction and disease pathogenesis .
2009	Amelioration of Murine Dry Eye Disease by Topical Antagonist to Chemokine Receptor 2 86	Topical application of CCR2 antagonist is associated with significant improvement in dry eye disease and is reflected by a decrease in inflammation at the clinical, molecular, and cellular levels.